CAJ | 학술논문

背景：临床可以采用冠状动脉支架置入治疗各种冠状动脉狭窄病变，术中可以选择药物洗脱性支架和裸金属支架等不同的支架类型，但不同厂家生产的支架在治疗效果和安全性等方面可能存在一定的差异。目的：探讨不同厂家可降解涂层雷帕霉素洗脱支架在冠状动脉狭窄病变处理中的安全性。方法：纳入冠状动脉狭窄病变患者196例，其中男116例，女80例，年龄37-81岁，均分为两组治疗，分别置入微创公司生产的Firebird可降解涂层雷帕霉素洗脱支架与乐普公司生产的Partner可降解涂层雷帕霉素洗脱支架。治疗后随访12个月，对比两组的再狭窄率、急性心肌梗死发生率、冠状动脉旁路移植或再次经皮冠状动脉介入治疗率及死亡率。结果与结论：随访12个月，两组再狭窄率、急性心肌梗死发生率、冠状动脉旁路移植或再次经皮冠状动脉介入治疗率及死亡率比较差异均无显著性意义(P >0.05)。经随访，两组均未发生与支架材料相关的不良反应。表明在治疗冠状动脉狭窄病变的过程中，置入不同品牌的可降解涂层雷帕霉素洗脱支架均可获得良好的效果，无不良反应发生，具有一定的安全性。
배경：림상가이채용관상동맥지가치입치료각충관상동맥협착병변，술중가이선택약물세탈성지가화라금속지가등불동적지가류형，단불동엄가생산적지가재치료효과화안전성등방면가능존재일정적차이。목적：탐토불동엄가가강해도층뢰파매소세탈지가재관상동맥협착병변처리중적안전성。방법：납입관상동맥협착병변환자196례，기중남116례，녀80례，년령37-81세，균분위량조치료，분별치입미창공사생산적Firebird가강해도층뢰파매소세탈지가여악보공사생산적Partner가강해도층뢰파매소세탈지가。치료후수방12개월，대비량조적재협착솔、급성심기경사발생솔、관상동맥방로이식혹재차경피관상동맥개입치료솔급사망솔。결과여결론：수방12개월，량조재협착솔、급성심기경사발생솔、관상동맥방로이식혹재차경피관상동맥개입치료솔급사망솔비교차이균무현저성의의(P >0.05)。경수방，량조균미발생여지가재료상관적불량반응。표명재치료관상동맥협착병변적과정중，치입불동품패적가강해도층뢰파매소세탈지가균가획득량호적효과，무불량반응발생，구유일정적안전성。
BACKGROUND:Coronary artery stents can be used in clinical treatment of various lesions due to coronary artery stenosis, and different types of drug-eluting stents and bare metal stents can be used surgicaly. However, there are some differences in the therapeutic efficacy and safety among the stents made in different manufacturers. OBJECTIVE:To explore the safety of biodegradable sirolimus eluting stents from different manufacturers in the treatment of coronary artery stenosis. METHODS:Totaly 193 patients with coronary artery stenosis were enroled, including 116 males and 80 females, aged 37-81 years old. These patients were equaly divided into two groups and respectively treated with Firebird stent (MicroPort) and Partner stent (LOOP INC). Patients were folowed up for 12 months, and the restenosis rate,incidence of acute myocardial infarction, rate of coronary artery bypass graft or secondary percutaneous coronary artery interventional therapy, and mortality rate were compared between two groups. RESULTS AND CONCLUSION:After 12 months of folowed-up, there was no difference in the restenosis rate, incidence of acute myocardial infarction, rate of coronary artery bypass graft or secondary percutaneous coronary artery interventional therapy, and mortality rate between two groups (P> 0.05). During the folow-up, no adverse reaction occurred in both two groups. These findings indicate that different brands of biodegradable sirolimus eluting stents can obtain good outcomes in the treatment of coronary artery stenosis, have no adverse reaction, and exhibit a certain degree of security.